Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma
Introduction We report two cases of renal cell carcinoma with brain metastases that showed remarkable responses to cabozantinib. Case presentation (Case 1) A 70‐year‐old man with cT3aN0M0 clear cell renal cell carcinoma underwent radical nephrectomy and developed multiple brain metastases 2 months p...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12459 |
| _version_ | 1818234467885514752 |
|---|---|
| author | Takashi Nakagawa Toshiki Kijima Naoki Imasato Akihiko Nagoshi Gaku Nakamura Toshitaka Uematsu Issei Suzuki Daisaku Nishihara Takao Kamai |
| author_facet | Takashi Nakagawa Toshiki Kijima Naoki Imasato Akihiko Nagoshi Gaku Nakamura Toshitaka Uematsu Issei Suzuki Daisaku Nishihara Takao Kamai |
| author_sort | Takashi Nakagawa |
| collection | DOAJ |
| description | Introduction We report two cases of renal cell carcinoma with brain metastases that showed remarkable responses to cabozantinib. Case presentation (Case 1) A 70‐year‐old man with cT3aN0M0 clear cell renal cell carcinoma underwent radical nephrectomy and developed multiple brain metastases 2 months postoperatively. The brain lesions regressed after stereotactic radiotherapy followed by ipilimumab plus nivolumab therapy, but a new brain metastasis that caused hemiplegia developed after 6 months and showed no response to stereotactic radiotherapy. However, complete remission was achieved, and hemiplegia ceased within 2 weeks of cabozantinib therapy. (Case 2) A 63‐year‐old man with cT3aN0M1 clear cell renal cell carcinoma and brain metastases underwent upfront cytoreductive nephrectomy. The brain lesions progressed rapidly 1 month postoperatively. The lesions disappeared 2 weeks after cabozantinib plus nivolumab therapy. Conclusion Cabozantinib, alone or in combination with immune checkpoint inhibitors, may be a viable option for clear cell renal cell carcinoma with brain metastases. |
| first_indexed | 2024-12-12T11:38:33Z |
| format | Article |
| id | doaj.art-e1be4020cbaf42aeb10ba580d46fdf81 |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-12-12T11:38:33Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-e1be4020cbaf42aeb10ba580d46fdf812022-12-22T00:25:36ZengWileyIJU Case Reports2577-171X2022-07-015429329610.1002/iju5.12459Efficacy of cabozantinib therapy for brain metastases from renal cell carcinomaTakashi Nakagawa0Toshiki Kijima1Naoki Imasato2Akihiko Nagoshi3Gaku Nakamura4Toshitaka Uematsu5Issei Suzuki6Daisaku Nishihara7Takao Kamai8Department of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanDepartment of Urology Dokkyo Medical University Shimotsuga Tochigi JapanIntroduction We report two cases of renal cell carcinoma with brain metastases that showed remarkable responses to cabozantinib. Case presentation (Case 1) A 70‐year‐old man with cT3aN0M0 clear cell renal cell carcinoma underwent radical nephrectomy and developed multiple brain metastases 2 months postoperatively. The brain lesions regressed after stereotactic radiotherapy followed by ipilimumab plus nivolumab therapy, but a new brain metastasis that caused hemiplegia developed after 6 months and showed no response to stereotactic radiotherapy. However, complete remission was achieved, and hemiplegia ceased within 2 weeks of cabozantinib therapy. (Case 2) A 63‐year‐old man with cT3aN0M1 clear cell renal cell carcinoma and brain metastases underwent upfront cytoreductive nephrectomy. The brain lesions progressed rapidly 1 month postoperatively. The lesions disappeared 2 weeks after cabozantinib plus nivolumab therapy. Conclusion Cabozantinib, alone or in combination with immune checkpoint inhibitors, may be a viable option for clear cell renal cell carcinoma with brain metastases.https://doi.org/10.1002/iju5.12459brain metastasescabozantinibclear cell renal cell carcinomaimmunotherapyradiotherapy |
| spellingShingle | Takashi Nakagawa Toshiki Kijima Naoki Imasato Akihiko Nagoshi Gaku Nakamura Toshitaka Uematsu Issei Suzuki Daisaku Nishihara Takao Kamai Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma IJU Case Reports brain metastases cabozantinib clear cell renal cell carcinoma immunotherapy radiotherapy |
| title | Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma |
| title_full | Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma |
| title_fullStr | Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma |
| title_full_unstemmed | Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma |
| title_short | Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma |
| title_sort | efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma |
| topic | brain metastases cabozantinib clear cell renal cell carcinoma immunotherapy radiotherapy |
| url | https://doi.org/10.1002/iju5.12459 |
| work_keys_str_mv | AT takashinakagawa efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma AT toshikikijima efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma AT naokiimasato efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma AT akihikonagoshi efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma AT gakunakamura efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma AT toshitakauematsu efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma AT isseisuzuki efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma AT daisakunishihara efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma AT takaokamai efficacyofcabozantinibtherapyforbrainmetastasesfromrenalcellcarcinoma |